Tier 2 — strong

Abnormal glycine betaine content of the blood and urine of diabetic and renal patients

M Lever, P C Sizeland, L M Bason, C M Hayman, R A Robson, S T Chambers
Clinica chimica acta; international journal of clinical chemistry 1994 230(1):69-79

Bibliography

PubMed
PMID 7850995
DOI
10.1016/0009-8981(94)90090-6
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignComparative clinical biomarker study
ModelHuman participants
SampleHealthy, diabetic and renal-disease groups
InterventionMeasured betaine status and related metabolites; no randomized TMG treatment
DurationCross-sectional blood and urine assessment
EndpointsDiabetes; Kidney disease; Betaine loss

What the study showed, in plain terms

Published in 1994, this source examined human observational and biomarker research. Design: Comparative clinical biomarker study. Sample/model: Healthy, diabetic and renal-disease groups. The exposure or intervention was Measured betaine status and related metabolites; no randomized TMG treatment. Follow-up or treatment period: Cross-sectional blood and urine assessment.

Urinary betaine was often elevated in diabetes and kidney disease; circulating and urinary patterns differed.

Observational exposure analysis: residual confounding and reverse causation remain possible. Associations do not establish that betaine supplementation causes the same outcome.

Continue with TMG Data Center

Continue with TMG for Weight Loss: Body-Fat Findings and Their Limits

Key findings

  • Urinary betaine was often elevated in diabetes and kidney disease; circulating and urinary patterns differed.
  • The recorded outcome domains were Diabetes; Kidney disease; Betaine loss.
  • The result applies to the tested exposure: Measured betaine status and related metabolites; no randomized TMG treatment; Cross-sectional blood and urine assessment.

What this study can and cannot tell us

  • Observational exposure analysis: residual confounding and reverse causation remain possible. Associations do not establish that betaine supplementation causes the same outcome.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Dietary Choline and Betaine Are Not Associated With the Risk of Type 2 Diabetes. A Systematic Review and Meta-Analysis of Observational Studies
Elham Sharifi-Zahabi et al. · Journal of diabetes research · 2026
Tier 2
Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes
Ana Maria Grizales et al. · The Journal of clinical endocrinology and metabolism · 2018
Tier 4
High Betaine, a Trimethylamine N-Oxide Related Metabolite, Is Prospectively Associated with Low Future Risk of Type 2 Diabetes Mellitus in the PREVEND Study
Erwin Garcia et al. · Journal of clinical medicine · 2019
Tier 4
Associations between Serum Betaine, Methyl-Metabolizing Genetic Polymorphisms and Risk of Incident Type 2 Diabetes: A Prospective Cohort Study in Community-Dwelling Chinese Adults
Xiaoting Lu et al. · Nutrients · 2022
Tier 4
Dietary Choline and Betaine and Risk of CVD: A Systematic Review and Meta-Analysis of Prospective Studies
Katie A Meyer et al. · Nutrients · 2017
Tier 4
Association of choline and betaine with the risk of cardiovascular disease and all-cause mortality: Meta-analysis
Qinglin Yang et al. · European journal of clinical investigation · 2023

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology